Praxis Precision Medicines Non-GAAP EPS of -$3.23 beats by $0.40
- Praxis Precision Medicines press release (PRAX): Q3 Non-GAAP EPS of -$3.23 beats by $0.40.
As of September 30, 2026, Praxis had $1.3 billion in cash, cash equivalents and marketable securities, compared to $926.1 million in cash, cash equivalents and marketable securities as of December 31, 2025. This increase of $359.9
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.